ASPG and acute lymphoblastic leukemia: This may be owed to the demand for the intensity of asparaginase treatment in children with ALL in the intermediate and high-risk groups such that the use of a full course of asparaginase has an important impact on the prognosis of these patients, and insufficient exposure to asparaginase will lead to an increased risk of relapse.